2010
May 18, 2010
Pearl Therapeutics’ Data for its Combination Bronchodilator Product, PT003, Support the Potential for Improvement in the Treatment of Patients with COPD
May 17, 2010
Pearl Therapeutics Receives TiE50 Entrepreneur Award
May 5, 2010
Pearl Therapeutics’ Bronchodilator Combination Therapeutic for COPD to Be Presented at the American Thoracic Society Annual Meeting
March 29, 2010
Pearl Therapeutics Announces Positive Results from Phase 1 Trial of PT003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial
February 1, 2010
Pearl Therapeutics Raises $15 Million to Advance PT003, LAMA/LABA Combination Bronchodilator for COPD, into Phase 2b Study
January 6, 2010
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
January 4, 2010
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Formoterol Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
2009
November 23, 2009
Pearl Therapeutics Appoints Howie Rosen to Board of Directors
March 02, 2009
Pearl Therapeutics Appoints Perry Karsen as CEO
February 24, 2009
Pearl Therapeutics Secures $8 Million in Debt Financing
2008
July 02, 2008
Pearl Therapeutics Closes $18 Million Financing
2007
December 20, 2007
Pearl Therapeutics, Inc. Expands Its Senior Management Team with Top Talent in Clinical Development and Regulatory Affairs
September 04, 2007
Pearl Therapeutics Raises $15.5 Million in Private Financing